

Bone-targeted agents for the management of breast cancer patients with bone metastases

Dwan-Ying Chang
Visiting Staff,
Department of Oncology,
National Taiwan University Hospital & National Taiwan University Cancer Center
Taipei, Taiwan

Despite advances in adjuvant therapy for breast cancer, bone remains the most common site of recurrence. Although novel agent and target therapy treatment outcome for breast cancer are outstanding.

The goal of BTA therapy for these patients is palliative and focused on maximizing the duration and quality of their life, while concurrently minimizing any disease or treatment-related complications. Bone metastases predispose patients to reduced survival, pain, impaired quality of life and the development of skeletal-related events. With an increased understanding of the pathophysiology of bone metastasis, effective treatments for their management have evolved and are now in widespread clinical use.

Dr. Chang's speech will discuss the pathogenesis of bone metastases and review the key clinical evidence for the efficacy and safety of currently available systemic bone-targeted therapies in breast cancer patients with an emphasis on bisphosphonates and the receptor activator of nuclear factor kappa B ligand (RANKL) inhibitors. We will also discuss novel strategies and therapies currently in development. Follow by the guideline update, how to implement in the practice will be share by the speaker.